Refine Search

New Search

Results: 17

(searched for: doi:10.3816/clml.2011.n.029)
Save to Scifeed
Page of 1
Articles per Page
by
Show export options
  Select all
Published: 24 December 2020
by Wiley
American Journal of Hematology, Volume 96, pp 258-269; doi:10.1002/ajh.26082

The publisher has not yet granted permission to display this abstract.
, Li Xu, Chun Cao, Juan Feng, Hai-Long Tang, Mi-Mi Shu, ,
Published: 1 April 2019
OncoTargets and Therapy, pp 2751-2766; doi:10.2147/ott.s191179

Abstract:
Rituximab-based combination therapy in patients with Waldenström macroglobulinemia: a systematic review and meta-analysis
Published: 17 October 2018
by Wiley
American Journal of Hematology, Volume 94, pp 266-276; doi:10.1002/ajh.25292

The publisher has not yet granted permission to display this abstract.
Blood Cancer Journal, Volume 8, pp 1-7; doi:10.1038/s41408-018-0076-5

Abstract:
Waldenström macroglobulinemia is often an indolent disorder, and many patients are candidates for observation with careful monitoring. For symptomatic patients, one must distinguish between those patients whose symptoms are related to immunologic manifestations associated with the IgM monoclonal protein and those that have symptoms related to progressive marrow and nodal infiltration with lymphoplasmacytic lymphoma. In Waldenström macroglobulinemia, the driver for therapy in the majority of patients is progressive anemia, secondary to bone marrow replacement by lymphoplasmacytic lymphoma. Recent introduction of MYD88 mutational analysis has been very useful for diagnostic purposes but is unclear what effect it might have on the prognosis or response rate to therapy. An algorithm is provided on the management of asymptomatic individuals and the sequence used for chemotherapeutic intervention of symptomatic patients.
Maddalena Mazzucchelli, Anna Maria Frustaci, Marina Deodato, ,
Mediterranean Journal of Hematology and Infectious Diseases, Volume 10; doi:10.4084/mjhid.2018.004

Abstract:
Waldenstrom Macroglobulinemia is a rare lymphoproliferative disorder with distinctive clinical features.Diagnostic and prognostic charactrization in WM significantly changed with the discovery of two molecular markers: MYD88 and CXCR4. Mutational status of these latter influences both clinical presentation and prognosis and demonstrated therapeutic implications.Treatment choice in Waldemstrom disease is strictly guided by patients age and characteristics, specific goals of therapy, necessity for rapid disease control, risk of treatment-related neuropathy, disease characteristics, risk of immunosuppression or secondary malignancies and potential for future autologous stem cell transplantation.Therapeutic landscape has expanded during the last years and the approval of ibrutinib, the first drug approved for Waldenstrom Macroglobulinemia, represents an important step forward for a better management of the disease.
, Stephen M. Ansell, Rafael Fonseca, Asher Chanan-Khan, Robert A. Kyle, Shaji K. Kumar, Joseph R. Mikhael, Thomas E. Witzig, Michelle Mauermann, Angela Dispenzieri, et al.
Published: 1 September 2017
JAMA Oncology, Volume 3, pp 1257-1265; doi:10.1001/jamaoncol.2016.5763

The publisher has not yet granted permission to display this abstract.
Morie A. Gertz
Published: 17 January 2017
by Wiley
American Journal of Hematology, Volume 92, pp 209-217; doi:10.1002/ajh.24557

The publisher has not yet granted permission to display this abstract.
Prashant Kapoor, Stephen M. Ansell,
Cancer Treatment and Research, Volume 169, pp 321-361; doi:10.1007/978-3-319-40320-5_16

The publisher has not yet granted permission to display this abstract.
, A. Morales-Gonzalez, F. Sanchis-Gomar, , C. Fiuza-Luces, , , N. Garatachea, A. Lucia,
Critical Reviews in Oncology/Hematology, Volume 105, pp 118-126; doi:10.1016/j.critrevonc.2016.06.004

The publisher has not yet granted permission to display this abstract.
Published: 1 September 2015
Blood Reviews, Volume 29, pp 301-319; doi:10.1016/j.blre.2015.03.001

The publisher has not yet granted permission to display this abstract.
Published: 23 March 2015
by Wiley
American Journal of Hematology, Volume 90, pp 346-354; doi:10.1002/ajh.23922

The publisher has not yet granted permission to display this abstract.
Horace T. B. Ho, Joanne Wang
Published: 29 August 2014
by Wiley
Drug Transporters pp 107-126; doi:10.1002/9781118705308.ch7

The publisher has not yet granted permission to display this abstract.
Ho Sup Lee, Kihyun Kim, Dok Hyun Yoon, , , , Hyeon Seok Eom, Hyewon Lee, Inho Kim, Won Sik Lee, et al.
BioMed Research International, Volume 2014, pp 1-7; doi:10.1155/2014/253243

Abstract:
Waldenström’s macroglobulinemia (WM) is a B-cell proliferative malignancy characterized by immunoglobulin M monoclonal gammopathy and bone marrow infiltration by lymphoplasmacytic cells. Clinical features and cytogenetics of WM in Asia including Republic of Korea remain unclear. Moreover, no study has reported treatment outcomes in patients with WM treated with novel agent combined with conventional chemotherapy. This study investigated clinical features and assessed treatment outcomes with novel agent and conventional chemotherapy in Republic of Korea. Data from all (n=71) patients with newly diagnosed WM at 17 hospitals who received chemotherapy between January 2005 and December 2012 were collected retrospectively. The median age of patients was 66 years (range: 37–92 years) and male to female ratio was 5 : 1. Patients treated with novel agent combined chemotherapy displayed higher overall response rate (ORR) compared to conventional chemotherapy alone (92.9% versus 52.6%,P=0.006). The 5-year overall survival rate was 62.6% (95% confidence interval: 34.73–111.07). Use of novel agents produced higher ORR but survival benefit was not apparent due to the small number of patients and short follow-up duration. Further studies are needed to confirm the efficacy of novel agents in patients with WM.
Published: 20 June 2013
by Wiley
American Journal of Hematology, Volume 88, pp 703-711; doi:10.1002/ajh.23472

The publisher has not yet granted permission to display this abstract.
, , Maria Cecilia Goldaniga, , , Marina Motta, Pietro Pioltelli, Guido Gini, Claudia Barate', Annamaria Luraschi, et al.
Clinical Lymphoma Myeloma and Leukemia, Volume 13, pp 231-234; doi:10.1016/j.clml.2013.02.011

The publisher has not yet granted permission to display this abstract.
Published: 17 April 2012
by Wiley
American Journal of Hematology, Volume 87, pp 503-510; doi:10.1002/ajh.23192

The publisher has not yet granted permission to display this abstract.
Page of 1
Articles per Page
by
Show export options
  Select all
Back to Top Top